HNB
CRNX icon

Huntington National Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Huntington National Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8K Sell
573
-46
-7% -$2.06K ﹤0.01% 1635
2025
Q4 		$28.8K Buy
619
+24
+4% +$1.07K ﹤0.01% 1452
2025
Q3 		$24.8K Sell
595
-32
-5% -$1.02K ﹤0.01% 1521
2025
Q2 		$18K Buy
627
+78
+14% +$2.41K ﹤0.01% 1613
2025
Q1 		$18.4K Buy
549
+54
+11% +$2.02K ﹤0.01% 1546
2024
Q4 		$25.3K Sell
495
-66
-12% -$3.69K ﹤0.01% 1469
2024
Q3 		$28.7K Sell
561
-19
-3% -$980 ﹤0.01% 1399
2024
Q2 		$26K Sell
580
-3
-0.5% -$139 ﹤0.01% 1379
2024
Q1 		$27.3K Sell
583
-266
-31% -$10.4K ﹤0.01% 1365
2023
Q4 		$30.2K Sell
849
-19
-2% -$583 ﹤0.01% 1287
2023
Q3 		$25.8K Sell
868
-325
-27% -$6.7K ﹤0.01% 1272
2023
Q2 		$21.5K Buy
1,193
+344
+41% +$6.86K ﹤0.01% 1339
2023
Q1 		$13.6K Buy
+849
New +$15.7K ﹤0.01% 1446

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Huntington National Bank's CRNX Position: Q1 2026 in Review

Huntington National Bank reduced its Crinetics Pharmaceuticals (CRNX) stake by 7.4% in Q1 2026, selling an estimated $2.06K and leaving 573 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Huntington National Bank first reported a position in CRNX in Q1 2023 and has held it in 13 quarters since. The position peaked at $30.2K in Q4 2023. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Huntington National Bank held 573 shares of Crinetics Pharmaceuticals worth $20.8K as of Q1 2026.
  • Huntington National Bank sold 46 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.06K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1635 holding.
  • Huntington National Bank first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Huntington National Bank's Crinetics Pharmaceuticals position peaked at $30.2K in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.